Loading…

Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy

Purpose The study aims to establish population pharmacokinetic (PPK) models of lamotrigine (LTG) in different age groups of epileptic children by nonlinear mixed effect modelling(NONMEM), and provide essential tools and theoretical basis for individualised optimal drug dose. Methods Cases of 473 epi...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 2017-04, Vol.73 (4), p.445-453
Main Authors: Zhang, Zhong-bin, Ji, Shuang-min, Han, Ying, Zang, Li-li, Wang, Ying-hui, Lu, Wei, Wang, Li, Wu, Ye
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c405t-8222c8def183da8f464a83f769379fcd75aad34cbce6f61fdd869c20308192c3
cites cdi_FETCH-LOGICAL-c405t-8222c8def183da8f464a83f769379fcd75aad34cbce6f61fdd869c20308192c3
container_end_page 453
container_issue 4
container_start_page 445
container_title European journal of clinical pharmacology
container_volume 73
creator Zhang, Zhong-bin
Ji, Shuang-min
Han, Ying
Zang, Li-li
Wang, Ying-hui
Lu, Wei
Wang, Li
Wu, Ye
description Purpose The study aims to establish population pharmacokinetic (PPK) models of lamotrigine (LTG) in different age groups of epileptic children by nonlinear mixed effect modelling(NONMEM), and provide essential tools and theoretical basis for individualised optimal drug dose. Methods Cases of 473 epileptic children were divided into infant, toddler and preschool age (≤6 years) ( n  = 211), school age (6–12 years) ( n  = 171) and adolescence age (>12 years) ( n  = 81). A total of 625 steady-state serum trough concentration samples were extracted. The clinical information included demography, medication, serum concentration data and blood biochemical parameters. PPK models of LTG were established by NONMEM program, using first-order absorption and elimination. Demography and drug combination was investigated for influence on apparent clearance (CL) and apparent volume of distribution ( V d). To assess the accuracy and precision of the different ages and whole-age model, the mean prediction error (MPE), mean absolute error (MAE) and root mean squared error (RMSE) were compared. Results The final model of LTG in different ages stage and whole age was as follows: (1) infant, toddler and preschool age CL = 0.715 × [(WEIG/16.25) 0.655 ] × (0.458 VPA ) × (1.99 IND ), V  = 10.4; (2) school age CL(L/h) = 1.01 × (WEIG/30) 0.399  × 0.465 VPA  × 1.98 IND , V d(L) = 17.7; (3) adolescence age CL(L/h) = 1.49 × (WEIG/51.5) 0.509  × 0.498 VPA  × 1.7 IND , V d(L) = 23.1; (4) whole age CL = 0.945 × [(WEIG/25) 0.645 ] × (0.463 VPA ) × (1.94 IND ), V  = 16.7 × (WEIG/25) 0.919 (WEIG, total body weight; VPA, combination with valproate, yes = 1, no = 0; IND, combination with enzyme inducer, yes = 1, no = 0). The values of MPE, MAE and RMSE in age-stage-specific models were less than the ones in the whole-age model, which suggests the age-stage-specific models have better precision and accuracy than the whole-age model. Conclusion PPK models of LTG in different age groups of epileptic children were successfully established. Weight and combination therapy were identified as significant covariates on LTG clearance. Compared with the whole-age model, the age-specific models are more reliable.
doi_str_mv 10.1007/s00228-016-2190-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1901749103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4320655621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-8222c8def183da8f464a83f769379fcd75aad34cbce6f61fdd869c20308192c3</originalsourceid><addsrcrecordid>eNqFkU1LHTEUhoNU9Hr1B3RTAt24mfbkY5LMslxaFYR24T7EfNyb25nJNJmh-O-NXi2lIIVAFu9z3pDzIPSewCcCID8XAEpVA0Q0lHTQ0CO0IpzRhgAn79AKgJFGdBJO0VkpewDSdsBO0ClVIDhr2xXa_0jT0ps5phFPO5MHY9PPOPo5Wjwk5_uCU8C9GdKc47YGOI7YxRB89uOMzdbjbU7L9IxtdhUoHttd7F3N8e8477CfYu-n8nCOjoPpi794udfo7tvXu811c_v96mbz5baxHNq5UZRSq5wPRDFnVOCCG8WCFB2TXbBOtsY4xu299SIIEpxTorMUGCjSUcvW6PJQO-X0a_Fl1kMs1ve9GX1aiq6LIpJ3BNj_UdUKVRdVzxp9_AfdpyWP9R-VkhI4lwoqRQ6UzamU7IOechxMftAE9JMyfVCmqzL9pEzTOvPhpXm5H7z7M_HqqAL0AJQajVuf_3r6zdZHKBChnQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1877044780</pqid></control><display><type>article</type><title>Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy</title><source>Springer Nature</source><creator>Zhang, Zhong-bin ; Ji, Shuang-min ; Han, Ying ; Zang, Li-li ; Wang, Ying-hui ; Lu, Wei ; Wang, Li ; Wu, Ye</creator><creatorcontrib>Zhang, Zhong-bin ; Ji, Shuang-min ; Han, Ying ; Zang, Li-li ; Wang, Ying-hui ; Lu, Wei ; Wang, Li ; Wu, Ye</creatorcontrib><description>Purpose The study aims to establish population pharmacokinetic (PPK) models of lamotrigine (LTG) in different age groups of epileptic children by nonlinear mixed effect modelling(NONMEM), and provide essential tools and theoretical basis for individualised optimal drug dose. Methods Cases of 473 epileptic children were divided into infant, toddler and preschool age (≤6 years) ( n  = 211), school age (6–12 years) ( n  = 171) and adolescence age (&gt;12 years) ( n  = 81). A total of 625 steady-state serum trough concentration samples were extracted. The clinical information included demography, medication, serum concentration data and blood biochemical parameters. PPK models of LTG were established by NONMEM program, using first-order absorption and elimination. Demography and drug combination was investigated for influence on apparent clearance (CL) and apparent volume of distribution ( V d). To assess the accuracy and precision of the different ages and whole-age model, the mean prediction error (MPE), mean absolute error (MAE) and root mean squared error (RMSE) were compared. Results The final model of LTG in different ages stage and whole age was as follows: (1) infant, toddler and preschool age CL = 0.715 × [(WEIG/16.25) 0.655 ] × (0.458 VPA ) × (1.99 IND ), V  = 10.4; (2) school age CL(L/h) = 1.01 × (WEIG/30) 0.399  × 0.465 VPA  × 1.98 IND , V d(L) = 17.7; (3) adolescence age CL(L/h) = 1.49 × (WEIG/51.5) 0.509  × 0.498 VPA  × 1.7 IND , V d(L) = 23.1; (4) whole age CL = 0.945 × [(WEIG/25) 0.645 ] × (0.463 VPA ) × (1.94 IND ), V  = 16.7 × (WEIG/25) 0.919 (WEIG, total body weight; VPA, combination with valproate, yes = 1, no = 0; IND, combination with enzyme inducer, yes = 1, no = 0). The values of MPE, MAE and RMSE in age-stage-specific models were less than the ones in the whole-age model, which suggests the age-stage-specific models have better precision and accuracy than the whole-age model. Conclusion PPK models of LTG in different age groups of epileptic children were successfully established. Weight and combination therapy were identified as significant covariates on LTG clearance. Compared with the whole-age model, the age-specific models are more reliable.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-016-2190-2</identifier><identifier>PMID: 28064355</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Anticonvulsants - pharmacokinetics ; Biomedical and Life Sciences ; Biomedicine ; Child ; Child, Preschool ; Children &amp; youth ; China ; Epilepsy ; Humans ; Infant ; Pharmacokinetics and Disposition ; Pharmacology ; Pharmacology/Toxicology ; Triazines - pharmacokinetics</subject><ispartof>European journal of clinical pharmacology, 2017-04, Vol.73 (4), p.445-453</ispartof><rights>Springer-Verlag Berlin Heidelberg 2017</rights><rights>European Journal of Clinical Pharmacology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-8222c8def183da8f464a83f769379fcd75aad34cbce6f61fdd869c20308192c3</citedby><cites>FETCH-LOGICAL-c405t-8222c8def183da8f464a83f769379fcd75aad34cbce6f61fdd869c20308192c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27900,27901</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28064355$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Zhong-bin</creatorcontrib><creatorcontrib>Ji, Shuang-min</creatorcontrib><creatorcontrib>Han, Ying</creatorcontrib><creatorcontrib>Zang, Li-li</creatorcontrib><creatorcontrib>Wang, Ying-hui</creatorcontrib><creatorcontrib>Lu, Wei</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Wu, Ye</creatorcontrib><title>Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><addtitle>Eur J Clin Pharmacol</addtitle><description>Purpose The study aims to establish population pharmacokinetic (PPK) models of lamotrigine (LTG) in different age groups of epileptic children by nonlinear mixed effect modelling(NONMEM), and provide essential tools and theoretical basis for individualised optimal drug dose. Methods Cases of 473 epileptic children were divided into infant, toddler and preschool age (≤6 years) ( n  = 211), school age (6–12 years) ( n  = 171) and adolescence age (&gt;12 years) ( n  = 81). A total of 625 steady-state serum trough concentration samples were extracted. The clinical information included demography, medication, serum concentration data and blood biochemical parameters. PPK models of LTG were established by NONMEM program, using first-order absorption and elimination. Demography and drug combination was investigated for influence on apparent clearance (CL) and apparent volume of distribution ( V d). To assess the accuracy and precision of the different ages and whole-age model, the mean prediction error (MPE), mean absolute error (MAE) and root mean squared error (RMSE) were compared. Results The final model of LTG in different ages stage and whole age was as follows: (1) infant, toddler and preschool age CL = 0.715 × [(WEIG/16.25) 0.655 ] × (0.458 VPA ) × (1.99 IND ), V  = 10.4; (2) school age CL(L/h) = 1.01 × (WEIG/30) 0.399  × 0.465 VPA  × 1.98 IND , V d(L) = 17.7; (3) adolescence age CL(L/h) = 1.49 × (WEIG/51.5) 0.509  × 0.498 VPA  × 1.7 IND , V d(L) = 23.1; (4) whole age CL = 0.945 × [(WEIG/25) 0.645 ] × (0.463 VPA ) × (1.94 IND ), V  = 16.7 × (WEIG/25) 0.919 (WEIG, total body weight; VPA, combination with valproate, yes = 1, no = 0; IND, combination with enzyme inducer, yes = 1, no = 0). The values of MPE, MAE and RMSE in age-stage-specific models were less than the ones in the whole-age model, which suggests the age-stage-specific models have better precision and accuracy than the whole-age model. Conclusion PPK models of LTG in different age groups of epileptic children were successfully established. Weight and combination therapy were identified as significant covariates on LTG clearance. Compared with the whole-age model, the age-specific models are more reliable.</description><subject>Anticonvulsants - pharmacokinetics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children &amp; youth</subject><subject>China</subject><subject>Epilepsy</subject><subject>Humans</subject><subject>Infant</subject><subject>Pharmacokinetics and Disposition</subject><subject>Pharmacology</subject><subject>Pharmacology/Toxicology</subject><subject>Triazines - pharmacokinetics</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFkU1LHTEUhoNU9Hr1B3RTAt24mfbkY5LMslxaFYR24T7EfNyb25nJNJmh-O-NXi2lIIVAFu9z3pDzIPSewCcCID8XAEpVA0Q0lHTQ0CO0IpzRhgAn79AKgJFGdBJO0VkpewDSdsBO0ClVIDhr2xXa_0jT0ps5phFPO5MHY9PPOPo5Wjwk5_uCU8C9GdKc47YGOI7YxRB89uOMzdbjbU7L9IxtdhUoHttd7F3N8e8477CfYu-n8nCOjoPpi794udfo7tvXu811c_v96mbz5baxHNq5UZRSq5wPRDFnVOCCG8WCFB2TXbBOtsY4xu299SIIEpxTorMUGCjSUcvW6PJQO-X0a_Fl1kMs1ve9GX1aiq6LIpJ3BNj_UdUKVRdVzxp9_AfdpyWP9R-VkhI4lwoqRQ6UzamU7IOechxMftAE9JMyfVCmqzL9pEzTOvPhpXm5H7z7M_HqqAL0AJQajVuf_3r6zdZHKBChnQ</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Zhang, Zhong-bin</creator><creator>Ji, Shuang-min</creator><creator>Han, Ying</creator><creator>Zang, Li-li</creator><creator>Wang, Ying-hui</creator><creator>Lu, Wei</creator><creator>Wang, Li</creator><creator>Wu, Ye</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy</title><author>Zhang, Zhong-bin ; Ji, Shuang-min ; Han, Ying ; Zang, Li-li ; Wang, Ying-hui ; Lu, Wei ; Wang, Li ; Wu, Ye</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-8222c8def183da8f464a83f769379fcd75aad34cbce6f61fdd869c20308192c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anticonvulsants - pharmacokinetics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children &amp; youth</topic><topic>China</topic><topic>Epilepsy</topic><topic>Humans</topic><topic>Infant</topic><topic>Pharmacokinetics and Disposition</topic><topic>Pharmacology</topic><topic>Pharmacology/Toxicology</topic><topic>Triazines - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Zhong-bin</creatorcontrib><creatorcontrib>Ji, Shuang-min</creatorcontrib><creatorcontrib>Han, Ying</creatorcontrib><creatorcontrib>Zang, Li-li</creatorcontrib><creatorcontrib>Wang, Ying-hui</creatorcontrib><creatorcontrib>Lu, Wei</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Wu, Ye</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Zhong-bin</au><au>Ji, Shuang-min</au><au>Han, Ying</au><au>Zang, Li-li</au><au>Wang, Ying-hui</au><au>Lu, Wei</au><au>Wang, Li</au><au>Wu, Ye</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy</atitle><jtitle>European journal of clinical pharmacology</jtitle><stitle>Eur J Clin Pharmacol</stitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>73</volume><issue>4</issue><spage>445</spage><epage>453</epage><pages>445-453</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Purpose The study aims to establish population pharmacokinetic (PPK) models of lamotrigine (LTG) in different age groups of epileptic children by nonlinear mixed effect modelling(NONMEM), and provide essential tools and theoretical basis for individualised optimal drug dose. Methods Cases of 473 epileptic children were divided into infant, toddler and preschool age (≤6 years) ( n  = 211), school age (6–12 years) ( n  = 171) and adolescence age (&gt;12 years) ( n  = 81). A total of 625 steady-state serum trough concentration samples were extracted. The clinical information included demography, medication, serum concentration data and blood biochemical parameters. PPK models of LTG were established by NONMEM program, using first-order absorption and elimination. Demography and drug combination was investigated for influence on apparent clearance (CL) and apparent volume of distribution ( V d). To assess the accuracy and precision of the different ages and whole-age model, the mean prediction error (MPE), mean absolute error (MAE) and root mean squared error (RMSE) were compared. Results The final model of LTG in different ages stage and whole age was as follows: (1) infant, toddler and preschool age CL = 0.715 × [(WEIG/16.25) 0.655 ] × (0.458 VPA ) × (1.99 IND ), V  = 10.4; (2) school age CL(L/h) = 1.01 × (WEIG/30) 0.399  × 0.465 VPA  × 1.98 IND , V d(L) = 17.7; (3) adolescence age CL(L/h) = 1.49 × (WEIG/51.5) 0.509  × 0.498 VPA  × 1.7 IND , V d(L) = 23.1; (4) whole age CL = 0.945 × [(WEIG/25) 0.645 ] × (0.463 VPA ) × (1.94 IND ), V  = 16.7 × (WEIG/25) 0.919 (WEIG, total body weight; VPA, combination with valproate, yes = 1, no = 0; IND, combination with enzyme inducer, yes = 1, no = 0). The values of MPE, MAE and RMSE in age-stage-specific models were less than the ones in the whole-age model, which suggests the age-stage-specific models have better precision and accuracy than the whole-age model. Conclusion PPK models of LTG in different age groups of epileptic children were successfully established. Weight and combination therapy were identified as significant covariates on LTG clearance. Compared with the whole-age model, the age-specific models are more reliable.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28064355</pmid><doi>10.1007/s00228-016-2190-2</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-6970
ispartof European journal of clinical pharmacology, 2017-04, Vol.73 (4), p.445-453
issn 0031-6970
1432-1041
language eng
recordid cdi_proquest_miscellaneous_1901749103
source Springer Nature
subjects Anticonvulsants - pharmacokinetics
Biomedical and Life Sciences
Biomedicine
Child
Child, Preschool
Children & youth
China
Epilepsy
Humans
Infant
Pharmacokinetics and Disposition
Pharmacology
Pharmacology/Toxicology
Triazines - pharmacokinetics
title Population pharmacokinetic models of lamotrigine in different age groups of Chinese children with epilepsy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-25T09%3A10%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Population%20pharmacokinetic%20models%20of%20lamotrigine%20in%20different%20age%20groups%20of%20Chinese%20children%20with%20epilepsy&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Zhang,%20Zhong-bin&rft.date=2017-04-01&rft.volume=73&rft.issue=4&rft.spage=445&rft.epage=453&rft.pages=445-453&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-016-2190-2&rft_dat=%3Cproquest_cross%3E4320655621%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c405t-8222c8def183da8f464a83f769379fcd75aad34cbce6f61fdd869c20308192c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1877044780&rft_id=info:pmid/28064355&rfr_iscdi=true